Abstract
The effect of tumor/T-cell interactions on subsequent immune infiltration is undefined. Here, we report that preexposure of melanoma cells to cognate T cells enhanced the chemotaxis of new T cells in vitro. The effect was HLA class I–restricted and IFNg - dependent, as it was abolished by b2M-knockdown, MHC-blocking antibodies, JAK1 inhibitors, JAK1-silencing and IFNgR1-blocking antibodies. RNA sequencing (RNA-seq) of 73 melanoma metastases showed a significant correlation between the interferon-inducible p150 isoform of adenosine-deaminase-acting-on-RNA-1 (ADAR1) enzyme and immune infiltration. Consistent with this, cocultures of cognate melanoma/T-cell pairs led to IFNg -dependent induction of ADAR1-p150 in the melanoma cells, as visualized in situ using dynamic cell blocks, in ovo using fertilized chick eggs, and in vitro with Western blots. ADAR1 staining and RNA-seq in patient-derived biopsies following immunotherapy showed a rise in ADAR1-p150 expression concurrently with CD8þ cell infiltration and clinical response. Silencing ADAR1-p150 abolished the IFNg-driven enhanced T-cell migration, confirming its mechanistic role. Silencing and overexpression of the constitutive isoform of ADAR1, ADAR1-p110, decreased and increased T-cell migration, respectively. Chemokine arrays showed that ADAR1 controls the secretion of multiple chemokines from melanoma cells, probably through microRNA-mediated regulation. Chemokine receptor blockade eliminated the IFNg-driven T-cell chemotaxis. We propose that the constitutive ADAR1 downregulation observed in melanoma contributes to immune exclusion, whereas antigen-specific T cells induce ADAR1-p150 by releasing IFNg, which can drive T-cell infiltration.
Original language | English |
---|---|
Pages (from-to) | 1127-1140 |
Number of pages | 14 |
Journal | Cancer Immunology Research |
Volume | 10 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2022 |
Externally published | Yes |
Bibliographical note
Funding Information:N. Margolis reports grants from Israel Science Foundation IPMP; and grants from Samueli Foundation during the conduct of the study. H. Moalem reports grants from Israel Science Foundation; and grants from Samueli Foundation during the conduct of the study. T. Meirson reports personal fees from TyrNovo outside the submitted work. B. Vizel reports grants from Israel Science Foundation; and grants from Samueli Foundation during the conduct of the study. M.J. Besser reports personal fees from KSQ Therapeutics, Gilboa Therapeutics, Sartorius; and personal fees from MSD outside the submitted work. G. Markel reports grants from Israel Science foundation; and grants from Samueli Foundation during the conduct of the study; personal fees from 4C Biomed, Starget, NucleAI, BeyondAir, MSD, Roche; grants and personal fees from BMS, Novartis; and grants and personal fees from Sanofi outside the submitted work. No disclosures were reported by the other authors.
Funding Information:
G. Markel was supported by grant from Israel Science foundation (IPMP 3956) and grant for integrative immuno-oncology from the Samueli Foundation.
Publisher Copyright:
©2022 American Association for Cancer Research.